Libo Pharma Corp.

NT$25.40As of Sun 8 Nov 2026, 12:00 UTC
TPEx:7888Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (52.97%)
Pharmaceutical Preparations
Beta (5Y) —
PE TTM —
TSR TTM —
Mkt cap NT$1.911B
ROIC (34.54%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$31
21.91%
(64.28%)
Buy 9|0|8|3|8
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.42
0.47
0.50
0.50
7.57%
9.71%
22.71%
25.13%
RevenueNT$M
93.32
91.47
88.86
89.64
6.40%
(1.56%)
(3.17%)
(2.75%)
Peers (US$57.72M)
Cap (US$)
PE
57.85M
8.731x
Capital
TTM
5Y
10Y
Leveragex
1.445
(0.019)
(0.020)
EBIT/Intx
0.916
0.427
0.426
Own earn%
(89.57)
170.17
173.67
Sh yield%
21.98
44.61
42.70
Owners
Insiders/Inst%
4.29
21.42
Short interest%
4.17
SBC / revenue%
3.94
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
7–16
$1 testx
0.1
Incr. ROIC%
50